Share This:
https://ntp.niehs.nih.gov/go/16735

TDMS Study 96021-01 Pathology Tables

NTP Experiment-Test: 96021-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                           TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153)                       Date: 06/05/03
Route: GAVAGE                                                                                                     Time: 11:02:41

                                                      53 WEEK SSAC FINAL#1




       Facility:  Battelle Columbus Laboratory

       Chemical CAS #:  35065-27-1

       Lock Date:  01/16/02

       Cage Range:  All

       Reasons For Removal:    25017 Scheduled Sacrifice

       Removal Date Range:     08/23/99 - 08/24/99

       Treatment Groups:       Include 001    0 UG/KG
                               Include 002    10 UG/KG
                               Include 003    100     UG/KG
                               Include 004    300     UG/KG
                               Include 005    1000    UG/KG
                               Include 006    3000    UG/KG





























a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 96021-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                           TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153)                       Date: 06/05/03  
Route: GAVAGE                                                                                                     Time: 11:02:41  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 UG/KG      10 UG/KG     100          300          1000         3000            
                                                                             UG/KG        UG/KG        UG/KG        UG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          98           86           98           98           98           80           
                                                                                                                                    
  Scheduled Sacrifice                                 13           12           13           13           13            9           
  Early Deaths                                                                                                                      
  Survivors                                                                                                                         
                                                                                                                                    
  Animals Examined Microscopically                     8            8            8            8            8            9           
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Thyroid Gland                                      (8)          (8)          (8)          (8)          (8)          (9)          
      C-Cell, Adenoma                                                                                      1 (13%)      1 (11%)     
      Follicle, Adenoma                                                          1 (13%)                                            
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Clitoral Gland                                     (1)                                                                           
      Carcinoma                                        1 (100%)                                                                     
   Ovary                                              (8)          (1)                       (1)          (1)          (9)          
      Sertoli Cell Tumor Malignant                                  1 (100%)                                                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   2                                                               
                                                                                                                                   
NTP Experiment-Test: 96021-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                           TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153)                       Date: 06/05/03  
Route: GAVAGE                                                                                                     Time: 11:02:41  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 UG/KG      10 UG/KG     100          300          1000         3000            
                                                                             UG/KG        UG/KG        UG/KG        UG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Mammary Gland                                      (8)          (2)          (2)          (2)                       (9)          
      Fibroadenoma                                                  2 (100%)     2 (100%)     2 (100%)                  2 (22%)     
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   3                                                               
                                                                                                                                   
NTP Experiment-Test: 96021-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                           TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153)                       Date: 06/05/03  
Route: GAVAGE                                                                                                     Time: 11:02:41  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 UG/KG      10 UG/KG     100          300          1000         3000            
                                                                             UG/KG        UG/KG        UG/KG        UG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)             1           3           3           2           1           2               
     Total Primary Neoplasms                            1           3           3           2           1           3               
                                                                                                                                    
   Total Animals with Benign Neoplasms                              2           3           2           1           2               
     Total Benign Neoplasms                                         2           3           2           1           3               
                                                                                                                                    
   Total Animals with Malignant Neoplasms               1           1                                                               
     Total Malignant Neoplasms                          1           1                                                               
                                                                                                                                    
   Total Animals with Metastatic Neoplasms                                                                                          
     Total Metastatic Neoplasm                                                                                                      
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   4                                                               
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------